{
    "organizations": [],
    "uuid": "a60961bfd5a67c18f6bd79bd481db428d2e6574c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-amgen-says-analysis-from-kyprolis/brief-amgen-says-analysis-from-kyprolis-trial-published-in-journal-of-clinical-oncology-idUSASB0C1B2",
    "ord_in_thread": 0,
    "title": "BRIEF-Amgen says Analysis From Kyprolis Trial Published in Journal Of Clinical Oncology",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 17 (Reuters) - Amgen Inc:\n* OVERALL SURVIVAL ANALYSIS FROM KYPROLISÂ® (CARFILZOMIB) PHASE 3 ASPIRE TRIAL PUBLISHED IN THE JOURNAL OF CLINICAL ONCOLOGY Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-18T05:30:00.000+02:00",
    "crawled": "2018-01-18T16:03:23.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "amgen",
        "inc",
        "overall",
        "survival",
        "analysis",
        "carfilzomib",
        "phase",
        "aspire",
        "trial",
        "published",
        "journal",
        "clinical",
        "oncology",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}